Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis

Additional Information

Published Date Dec 19, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3627
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis.

    To find out more about Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
4SC
Abbott
Abiogen
Access
Adherex
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisense Pharma
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocompatibles
Biocon
BioCryst Pharmaceuticals
Biogen Idec
BioInvent
Biolex
BioLineRx
Biomas
Bionovo
BioNumerik
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CuraGen
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Etubics
Exelixis
FasTrack Pharmaceuticals
Favrille
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Hayashibara
Heber Biotec
Heidelberg Pharma
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
IkerChem
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kalypsys
Keryx Biopharmaceuticals
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Labopharm
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Meda
MediGene
MedImmune
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
PanaGin
Patrys
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
POZEN
Pro-Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protherics
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rigel
Rosetta Genomics
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Senesco Technologies
Shire
Sigma-Tau
Simcere Pharmaceuticals
Spirogen
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Vaccinex
ValiRx
VBL Therapeutics
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
Wyeth
XBiotech
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
aflibercept
alemtuzumab
alvocidib
AME-133
amrubicin hydrochloride
Angiozyme
APG-101
ARQ-197
AS-101
AS-1411
bardoxolone methyl
belinostat
bevacizumab
bexarotene
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
BZL-101
canfosfamide hydrochloride
capecitabine
catumaxomab
cediranib
cenersen
cetuximab
cintredekin besudotox
cladribine
conatumumab
crolibulin
denileukin diftitox
dinaciclib
doxifluridine
dulanermin
elliptinium acetate
enzastaurin hydrochloride
epirubicin
everolimus
fosbretabulin tromethamine
galiximab
gataparsen
GT-111
HBP-347
HE-3235
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imetelstat
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interferon gamma
irinotecan bead
irinotecan hydrochloride
kahalalide F
lestaurtinib
litronesib
lonaprisan
lumiliximab
mapatumumab
MGN-1703
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
navitoclax
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
Oncohist
panitumumab
panobinostat
PAT-SC1
PBI-1402
PCI-24781
perifosine
pixantrone
plitidepsin
pralatrexate
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
raltitrexed
ramucirumab
razoxane
Reditux
regorafenib
retaspimycin
rhIFN-alpha
rituximab
romidepsin
sagopilone
seliciclib
sobuzoxane
SPC-2996
ß-lapachone
SU-6668
tegafur + uracil
tegafur + uracil + leucovorin
temsirolimus
teniposide
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
triciribine phosphate
TRU-016
TS-1
volasertib
vosaroxin
XL-147
XL-647
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis.
    To find out more about Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Pancreatic Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Pancreatic Cancer and Prostate Cancer. Learn More


Target Atlas in Renal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More